SOUTH SAN FRANCISCO, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that on October 9, 2006, the underwriters exercised in full their option to purchase 1.5 million shares of common stock associated with Exelixis’ public stock offering that priced at $8.40 per share, before underwriting discounts and commissions, on October 4, 2006. The exercise of the option to purchase the additional shares increases the size of the offering to a total of 11.5 million shares of common stock, resulting in net proceeds to Exelixis of approximately $90.5 million.
Goldman, Sachs & Co. is acting as the sole book-running manager for the offering. Cowen and Company, LLC is acting as the joint lead manager, and Banc of America Securities LLC and Piper Jaffray & Co. are acting as co-managers for the offering.
A registration statement relating to these securities has been filed with and declared effective by the Securities and Exchange Commission. The offering may be made only by means of a prospectus supplement and the accompanying prospectus. Copies of the final prospectus supplement and the accompanying prospectus may be obtained by sending a request to Goldman, Sachs & Co., Attn: Prospectus Department, 85 Broad Street, New York, New York 10004, Fax: 212-902-9316 or Email at prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Exelixis
Exelixis, Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutics that will potentially enhance the care and lives of patients with cancer and other serious diseases.
Exelixis, Inc.
CONTACT: Frank Karbe, Chief Financial Officer, +1-650-837-7565, orfkarbe@exelixis.com, or Charles Butler, Director, Corporate Communications,+1-650-837-7277, or cbutler@exelixis.com, both of Exelixis, Inc.
Web site: http://www.exelixis.com//
